Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.00)
# 461
Out of 4,918 analysts
62
Total ratings
52.38%
Success rate
12.76%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $28.04 | +10.56% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $13.08 | -31.19% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $33.68 | -2.02% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $118.91 | +59.78% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $88.23 | +13.34% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.83 | -8.79% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $290.31 | +34.34% | 4 | Mar 6, 2025 | |
| TEM Tempus AI | Downgrades: Neutral | $50 → $55 | $54.89 | +0.20% | 3 | Feb 25, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $55 | $41.42 | +32.79% | 1 | Feb 21, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $160 | $113.50 | +40.97% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $463.04 | +44.70% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $80 | $67.98 | +17.68% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $3.91 | +412.16% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,197.23 | +16.94% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $6 | $10.33 | -41.92% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.33 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $37.99 | +136.90% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $197.09 | +36.99% | 4 | Dec 20, 2023 |
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $28.04
Upside: +10.56%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $13.08
Upside: -31.19%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $33.68
Upside: -2.02%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $118.91
Upside: +59.78%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $88.23
Upside: +13.34%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.83
Upside: -8.79%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $290.31
Upside: +34.34%
Tempus AI
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $54.89
Upside: +0.20%
Guardant Health
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $41.42
Upside: +32.79%
Agilent Technologies
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $113.50
Upside: +40.97%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $463.04
Upside: +44.70%
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $67.98
Upside: +17.68%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $3.91
Upside: +412.16%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,197.23
Upside: +16.94%
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $10.33
Upside: -41.92%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.33
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $37.99
Upside: +136.90%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $197.09
Upside: +36.99%